Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trius Antibiotic Tedizolid Hits Old, New And In-Between Endpoints

Executive Summary

Tedizolid, a next-generation antibiotic from the same class as Pfizer’s Zyvox, has met all complicated skin infection endpoints for both a U.S. and European filing, and Trius plans submissions in second half 2013 and first half 2014, respectively. European partnering talks, meanwhile, have gained new intensity.

You may also be interested in...



Cubist Tedizolid Advisory Cmte. Review Will Gauge FDA’s Mood On Antibiotic “Breakpoints”

Cubist’s second-generation oxazolidineone is set for an FDA advisory committee review in March.

Next Up For Cubist: A Future That Includes Optimer, Trius

Cubist Pharmaceuticals will strengthen its position in the challenging antibiotic market with the acquisitions of two rivals, Optimer Pharmaceuticals and Trius Therapeutics. But it was Cubist’s current strength that allowed it to get those deals done on favorable, risk-sharing terms.

Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius

Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel